On March 21, 2023, Achieve Life Sciences, Inc. entered into an amendment (the Amendment") to its Cooperation Agreement with Dialectic Capital Management, LP (Dialectic") and related entities (collectively with Dialectic, the Stockholders") regarding certain changes to the composition of the Company's board of directors (the Board") and other related matters. Pursuant to the terms of the Amendment, the Company shall, no later than April 3, 2023, appoint three individuals (to the Board to fill three vacancies created by either (x) the departure of an incumbent member of the Board as designated in the Cooperation Agreement or (y) expanding the Board size to up to 11 directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.41 USD | 0.00% | +6.92% | +31.31% |
13/05 | Oppenheimer Adjusts Achieve Life Sciences Price Target to $11 From $18, Maintains Outperform Rating | MT |
09/05 | Transcript : Achieve Life Sciences, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.31% | 19Cr | |
+67.53% | 6.39TCr | |
-0.77% | 4.18TCr | |
+44.98% | 4.07TCr | |
-10.87% | 2.71TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr |
- Stock Market
- Equities
- ACHV Stock
- News Achieve Life Sciences, Inc.
- Achieve Life Sciences, Inc. Enters into an Amendment Cooperation Agreement with Dialectic Capital Management, Lp